{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 21,
  "pageCount": 29,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a biological mechanism diagram, a Kaplan-Meier survival curve, and IHC images to demonstrate the clinical impact of CD58 loss.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/21",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Axi-Cel Treated LBCL",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ece08aa-ab7d-459e-abee-8446ec172659",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Loss of costimulation can lead to reduced tumor killing from CAR T cells",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f382773d-53a9-45b5-9047-5625b15b4063",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.7,
        "y": 0.25
      },
      "kind": "image",
      "text": "CD58 pre-treatment and CD58 at relapse IHC images",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2eea0aa-65ef-4e26-9864-7d3bb41ee2d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Approximately 25% of patients LBCL patients treated with CD19 CAR T have mutated or absent CD58",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0660234-9ed1-4eba-a175-e3ba866a930b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "CD58 loss has also been observed across lymphoma subtypes and in other tumor types (myeloma, AML, colon CA, melanoma)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c911acce-b900-4789-aa4a-82de79ab10bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Majzner ASH Annual Meeting, 2020; Yan, X., et. Al., Blood Advances, 2022; Younes et. Al., Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance, Mod Pathol. 2023 Jun 28;36(10):1002568",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd58c29f-9c81-4c1c-a29d-579dcdb10d2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Aberrant CD58 expression in lymphoma associates with poor CD19 CAR T outcomes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c7595be-26d0-4344-aff2-05cc10412ed3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}